.png){kind=icon}
Rheumatoid Arthritis Drug Development Solutions
There remains a significant unmet need in the treatment of rheumatoid arthritis (RA): there is no cure, treatments are often inconvenient and expensive, and safety is still a concern. Covance understands the challenges faced in RA clinical development, and has the insight and experience to help you achieve success.
了解类风湿性关节炎行业需求
A trend towards more aggressive treatment under the 'treat to target' strategy
Steady market growth due in part to aging population
Movement towards early diagnosis and treatment of patients
Expanded range of treatment options including novel biologics and small molecules
Increasing availability of biosimilars making biologic treatments more accessible
Biosimilars to infliximab, etanercept and adalimumab all approved
The nature of RA trials and the current development landscape cause a number of challenges in many RA clinical development programs. Covance has developed solutions to overcome each of these and help you along the path to success.
RA drug development pain points.
- Competitive biologics marketplace
- Difficulty in identifying investigators and locating patients
- Suboptimal patient retention over long trial periods
- Inefficient trial design, eligibility creep and inconsistencies in both subjective and objective trial outcomes
- Increasing demand for patients due to a small percentage participating in trials
- Inconsistencies in trial outcomes, which may be linked to inappropriate or incorrect use of PRO measures
- Inefficient patient recruitment, often a result of the competitive RA trial environment
- 如果站点无法招募患者的数量，则延迟延迟
Extensive experience in rheumatoid arthritis clinical trials.
- Since 2012 Covance has managed30 RA studies与919sitesand2,796名患者
- Proven experience in meeting RA trial timelines
- We have performance metrics on more than1,400 rheumatologists
- Covance employmore than 1,200 RA-experienced staff, includingmore than 530 clinical research associatesand nearly150 project managers
Through our extensive experience in RA clinical trials we have accrued the operational and scientific expertise, along with the necessary infrastructure, to help you meet timelines and save costs in your RA clinical development program.
We know how to address the pain points of RA clinical trials.
Optimize study planning and speed patient enrollment with evidence-based approaches
Clinical knowledgebase housing超过40%global clinical trial data at any one time
Target patient populations for efficient recruitment
- Clinical trial opt-in patient initiative* currently withmore than 2,570 RApatients
- Incorporating global disease prevalence data to identify target patient populations
- Performance metrics onmore than1,400 Ph II–III RA investigatorssince 2012
- All RA study recruitment timelines achieved since 2012
- Specialty inflammatory biomarkers, e.g., GlycA, rheumatoid factor and hCRP
Identify and validate relevant biomarkers
- Flexible biomarker team offering feasibility, development, validation and production expertise
- More than 550assaysavailable in-house
Improve patient retention through education and support
- Established patient support system, including health education and appointment reminders
- Covance voice of patient insights used in trial design to ensure patient-centric trials
Develop biosimilars to compete in current environment
- Integrated biosimilars solutions team
- Covance has supported the development of107 unique biosimilarsin178 individual projectssince 2010
Optimize product pricing for successful market entry
Dedicated market access team experienced in demonstrating real-world value and ensuring optimal reimbursement, having supported numerous inflammation products globally
